

Correction

Correction: Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab

Xenofon Baraliakos¹, Joachim Listing², Jan Brandt¹, Angela Zink², Rieke Alten³, Gerd Burmester⁴, Erika Gromnica-Ihle⁵, Herbert Kellner⁶, Matthias Schneider⁷, Helmut Sörensen⁸, Henning Zeidler⁹, Martin Rudwaleit¹⁰, Joachim Sieper¹⁰ and Juergen Braun¹

¹ Rheumazentrum Ruhrgebiet, Herne, Ruhr University Bochum, Germany

² German Rheumatism Research Center, Berlin, Germany

³ Schlosspark Clinic, Berlin, Germany

⁴ Charité, University Medicine Berlin, Campus Mitte, Germany

⁵ Berlin-Buch Hospital, Berlin, Germany

⁶ Ludwig-Maximilians-University, Munich, Germany

⁷ Heinrich-Heine-University, Düsseldorf, Germany

⁸ Private Praxis, Berlin, Germany

⁹ Medical University of Hannover, Hanover, Germany

¹⁰ Charité, Medical University of Berlin, Campus Benjamin Franklin, Department of Rheumatology, Germany

Corresponding author: Juergen Braun, j.braun@rheumazentrum-ruhrgebiet.de

Published: 23 March 2005

This article is online at <http://arthritis-research.com/content/7/3/113>

© 2005 BioMed Central Ltd

Arthritis Research & Therapy 2005, **7**:113 (DOI 10.1186/ar1750)

After publication of this work [1], we noted that we inadvertently failed to include the complete list of all co-authors. The full list of authors has now been added and the Authors' contributions and Competing interests section modified accordingly.

Competing interests

Dr Braun and Dr Sieper have held consultancies and received research honoraria, speaker's honoraria and grants/research support from Centocor, Schering-Plough, Essex Pharma, Wyeth and Abbott. Dr Zeidler has received speaker's honoraria from Essex Pharma. Dr Burmester has held consultancies for Centocor, Essex Pharma, Wyeth and Abbott; has received honoraria from Centocor, Essex Pharma, Wyeth and Abbott; has been a member of a speaker's bureau for Centocor, Essex Pharma, Wyeth and Abbott; and has received grants/research support from Centocor, Essex Pharma and Abbott. The other authors declare no conflicts of interest.

Authors' contributions

XB: Preparation of data analysis, preparation of the manuscript and study coordination; JL, AZ: Data analysis and statistical evaluation; JB, MR: Monitoring and investigation of the patients and study coordination; RA, GB, EG-I, HK, MS, HS, HZ: clinical investigation; JS: Investigator, writing of the manuscript; JB: Idea, writing of the manuscript, principal investigator and responsible for the study.

References

1. Baraliakos, X, Listing, J, Brandt, J, Rudwaleit, M, Sieper, Braun, J: **Clinical response to withdrawal of anti-TNF therapy in patients with ankylosing spondylitis (AS) after 3 years of continuous treatment with Infliximab.** *Arthritis Res Ther* 2005, **7**:R439-R444.